Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18783
Abstract: Oral azacitidine (Oral‐AZA) maintenance therapy improved relapse‐free (RFS) and overall survival (OS) significantly versus placebo for AML patients in remission after intensive chemotherapy (IC) in the phase 3 QUAZAR AML‐001 study. Immune profiling was performed… read more here.
Keywords: cell; oral azacitidine; bone marrow; aml 001 ... See more keywords
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016293
Abstract: The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with AML in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell transplant. Eligible patients… read more here.
Keywords: aza; oral azacitidine; npm1 flt3; aml first ... See more keywords
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018254
Abstract: PTCL with T-follicular helper phenotype (PTCL-TFH) has recurrent mutations affecting epigenetic regulators, which may contribute to aberrant DNA methylation and chemoresistance. This phase 2 study evaluated oral azacitidine (CC-486), a DNA methyltransferase inhibitor, plus CHOP… read more here.
Keywords: ptcl tfh; oral azacitidine; ptcl; phase study ... See more keywords